1. PM2.5 induce the defective efferocytosis and promote atherosclerosis via HIF-1α activation in macrophage
   Shuang Liang et al, 2022, Nanotoxicology CrossRef
2. Inhibition of JAK2/STAT3/SOCS3 signaling attenuates atherosclerosis in rabbit
   Xilan Yang et al, 2020, BMC Cardiovascular Disorders CrossRef
3. The Potential of a Novel Class of EPAC-Selective Agonists to Combat Cardiovascular Inflammation
   Graeme Barker et al, 2017, Journal of Cardiovascular Development and Disease CrossRef
4. The Role of JAK/STAT Signaling Pathway and Its Downstream Influencing Factors in the Treatment of Atherosclerosis
   Xin Zhang et al, 2024, Journal of Cardiovascular Pharmacology and Therapeutics CrossRef
5. The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease
   Carlota Recio et al, 2017, Frontiers in Pharmacology CrossRef
6. The novel exchange protein activated by cyclic AMP 1 (EPAC1) agonist, I942, regulates inflammatory gene expression in human umbilical vascular endothelial cells (HUVECs)
   Jolanta Wiejak et al, 2019, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research CrossRef
7. Conventional therapies fail to target inflammation and immune imbalance in subjects with stable coronary artery disease: A system-based approach
   Divya Kapoor et al, 2014, Atherosclerosis CrossRef
8. The role of lnc-DC long non-coding RNA and SOCS1 in the regulation of STAT3 in coronary artery disease and type 2 diabetes mellitus
   Asieh Alikhah et al, 2018, Journal of Diabetes and its Complications CrossRef
9. Immune Regulators Regulated to Prevent Transplant Reactions
   Roel A. de Weger, 2014, Journal of the American College of Cardiology CrossRef
10. Peptides as Therapeutic Agents for Inflammatory-Related Diseases
    Sara La Manna et al, 2018, International Journal of Molecular Sciences CrossRef
11. Suppressor of Cytokine Signaling-1 Peptidomimetic Limits Progression of Diabetic Nephropathy
    Carlota Recio et al, 2017, Journal of the American Society of Nephrology CrossRef
12. Protective effect of suppressor of cytokine signalling 1‐based therapy in experimental abdominal aortic aneurysm
    Susana Bernal et al, 2021, British Journal of Pharmacology CrossRef
13. Gene delivery of suppressors of cytokine signaling (SOCS) inhibits inflammation and atherosclerosis development in mice
    Carlota Recio et al, 2015, Basic Research in Cardiology CrossRef
14. The future of EPAC-targeted therapies: agonism versus antagonism
    Euan Parnell et al, 2015, Trends in Pharmacological Sciences CrossRef
15. Suppressor of Cytokine Signaling 1–Derived Peptide Inhibits Janus Kinase/Signal Transducers and Activators of Transcription Pathway and Improves Inflammation and Atherosclerosis in Diabetic Mice
    Carlota Recio et al, 2014, Arteriosclerosis, Thrombosis, and Vascular Biology CrossRef
16. Protein Inhibitor of Activated STAT3 Suppresses Oxidized LDL-induced Cell Responses during Atherosclerosis in Apolipoprotein E-deficient Mice
    Rong Wang et al, 2016, Scientific Reports CrossRef
17. Effects of Di-(2-ethylhexyl) Phthalate on Lipid Metabolism by the JAK/STAT Pathway in Rats
    Yiyang Jia et al, 2016, International Journal of Environmental Research and Public Health CrossRef
18. MiR-455-5p serves as a biomarker of atherosclerosis and inhibits vascular smooth muscle cell proliferation and migration
    Xiang Zhang et al, 2021, Personalized Medicine CrossRef
19. Phosphatase and Tensin Homolog (PTEN) of Japanese Flounder—Its Regulation by miRNA and Role in Autophagy, Apoptosis and Pathogen Infection
    Wenrui Li et al, 2020, International Journal of Molecular Sciences CrossRef
20. The angiopoietin receptor Tie2 is atheroprotective in arterial endothelium
    Andrey Anisimov et al, 2023, Nature Cardiovascular Research CrossRef
21. Platelet regulation of myeloid suppressor of cytokine signaling 3 accelerates atherosclerosis
    Tessa J. Barrett et al, 2019, Science Translational Medicine CrossRef